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A B S T R A C T
Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a trinucleotide repeat expansion in the huntingtin (HTT) gene, which is expressed ubiquitously throughout the brain and peripheral tissues. Whilst the focus of much research has been on the cognitive, psychiatric and motor symptoms of HD, the extent of peripheral pathology and its potential impact on central symptoms has been less intensely explored. Disruption of the gastrointestinal microbiome (gut dysbiosis) has been recently reported in a number of neurological and psychiatric disorders, and therefore we hypothesized that it might also occur in HD. We have used 16S rRNA amplicon sequencing to characterize the gut microbiome in the R6/1 transgenic mouse model of HD, relative to littermate wild-type controls. We report that there is a significant difference in microbiota composition in HD mice at 12 weeks of age. Specifically, we observed an increase in Bacteriodetes and a proportional decrease in Firmicutes in the HD gut microbiome. In addition, we observed an increase in microbial diversity in male HD mice, compared to wild-type controls, but no differences in diversity were observed in female HD mice. The gut dysbiosis observed coincided with impairment in body weight gain despite higher food intake as well as motor deficits at 12 weeks of age. Gut dysbiosis was also associated with a change in the gut microenvironment, as we observed higher fecal water content in HD mice at 12 weeks of age. This study provides the first evidence of gut dysbiosis in HD.
Introduction
Huntington's disease (HD) is a progressive neurodegenerative disorder involving cognitive, psychiatric and motor symptoms. It is caused by the trinucleotide (CAG) repeat expansion in the huntingtin (HTT) gene, which is widely expressed in various cell types throughout the brain and peripheral tissues including the skeletal muscles, heart, and gut (Moffitt et al., 2009; Sathasivam et al., 1999; Sharp et al., 1995; The Huntington's Disease Collaborative Research Group, 1993) . The expression of this mutant protein leads to a cascade of molecular dysregulation and cellular dysfunction. HD patients typically exhibit motor, cognitive and affective symptoms which are highly comorbid with skeletal muscle atrophy, progressive weight loss, altered metabolic homeostasis and gastrointestinal (GI) dysfunction (Andrich et al., 2009; van der Burg et al., 2011) . Additionally, the presence of the mutant protein in the enteric nervous system, as well as intestinal epithelial cells along the GI tract, leads to the loss of neuropeptides in the gut, which are associated with abnormalities in gut function (van der Burg et al., 2011) .
The mammalian GI tract hosts a complex ecosystem of microbes which work symbiotically with the host. It has been established that gut microbiota are key modulators for the bi-directional communication between the gut and the brain, also known as the gut-brain-axis. Intestinal microbiota have been shown to influence neurodevelopment, brain function and behaviour (Clarke et al., 2013; Hoban et al., 2017; Ogbonnaya et al., 2015; Stilling et al., 2015) . The undesirable shift in microbiota composition, also known as gut dysbiosis, has been associated with the development of various gastrointestinal and metabolic diseases, including inflammatory bowel disease (IBD), obesity and diabetes (Greenblum et al., 2012; Qin et al., 2012; Turnbaugh et al., https://doi.org/10.1016/j.nbd.2018.09.001 Received 6 May 2018; Received in revised form 22 August 2018; Accepted 2 September 2018
